STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
The small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody to protect against Covid.
Invivyd, a small biotech company, is pursuing an injectable, low-dose monoclonal antibody as a potential alternative to Covid-19 vaccines. The company's candidate, VYD2311, recently reported successful results from a Phase 3 study, known as LIBERTY, which demonstrated its superior safety and tolerability compared to the established mRNA-based Covid vaccine, Comirnaty, developed by Pfizer.
After six days, 57% of participants who received VYD2311 reported common side effects such as headaches, chills, fatigue, or pain at the injection site, while 91% of those who received Comirnaty experienced the same side effects, a difference that was statistically significant. At 56 days post-injection, VYD2311 was also found to be better tolerated. Additionally, the study revealed that VYD2311 could be safely combined with Comirnaty.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
